ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,410,440, issued on Sept. 9, was assigned to Ascidian Therapeutics Inc. (Boston).
"ABCA4 trans-splicing molecules" was invented by Rebekka Krumbach (Boston), Scott Dooley (Boston), Akiko Doi (Boston), Kirk Burkhart (Boston), Jesse Gray (Boston), Lingtao Peng (Boston), Dennis Wu (Boston), Akiko Noma (Boston), Kirk Gosik (Boston), Shimyn Slomovic (Boston), Adam Clemens (Boston) and Robert Bell (Boston).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs); RNA exon editing molecules) capable of correcting mutations in the ABCA4 gene. Such molecules are useful...